[go: up one dir, main page]

WO2010036031A3 - Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same - Google Patents

Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same Download PDF

Info

Publication number
WO2010036031A3
WO2010036031A3 PCT/KR2009/005437 KR2009005437W WO2010036031A3 WO 2010036031 A3 WO2010036031 A3 WO 2010036031A3 KR 2009005437 W KR2009005437 W KR 2009005437W WO 2010036031 A3 WO2010036031 A3 WO 2010036031A3
Authority
WO
WIPO (PCT)
Prior art keywords
pauf
cancer
same
monoclonal antibody
human monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/005437
Other languages
French (fr)
Other versions
WO2010036031A2 (en
Inventor
Sang Seok Koh
Yang Soon Lee
Mi Jin Sohn
Su Jin Kim
Kyung Sook Yoo
Eun Hye Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2010036031A2 publication Critical patent/WO2010036031A2/en
Publication of WO2010036031A3 publication Critical patent/WO2010036031A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed are a PAUF protein associated with the onset of cancer, a human monoclonal antibody specific to the PAUF protein, and a nucleic acid molecule coding for the PAUF protein, and uses thereof. Closely correlated with the onset of cancer, the PAUF protein or the PAUF nucleic acid molecule can be used as a diagnostic marker or a therapeutic target. In addition, having the ability to bind specifically to PAUF presented on the surface of various cancer cells including pancreatic cancer cells, the anti-PAUF antibody or its functional fragment allows the diagnosis of cancer in the early stages thereof and can inhibit the growth, invasion or migration of cancer cells by inducing the cells to undergo apoptosis, and thus are useful in the diagnosis and treatment of cancer.
PCT/KR2009/005437 2008-09-23 2009-09-23 Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same Ceased WO2010036031A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0093106 2008-09-23
KR20080093106 2008-09-23

Publications (2)

Publication Number Publication Date
WO2010036031A2 WO2010036031A2 (en) 2010-04-01
WO2010036031A3 true WO2010036031A3 (en) 2010-06-24

Family

ID=42060277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/005437 Ceased WO2010036031A2 (en) 2008-09-23 2009-09-23 Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same

Country Status (2)

Country Link
KR (2) KR20100034720A (en)
WO (1) WO2010036031A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012128502A2 (en) * 2011-03-24 2012-09-27 한국생명공학연구원 Composition for promoting vasculogenesis comprising pauf
KR101373103B1 (en) * 2011-03-28 2014-03-11 연세대학교 산학협력단 Methods for Screening Therapeutics for Cancer Using Interaction between PAUF and Its Binding Partner
KR101250557B1 (en) * 2011-05-18 2013-04-03 국립암센터 PAUF-specific aptamer and therapeutic composition for treatment of pancreatic cancer comprising thereof
KR101856904B1 (en) * 2017-07-28 2018-05-11 동아대학교 산학협력단 Antibody specifically binding to PAUF and use thereof
WO2019022274A1 (en) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Antibody specifically binding to pauf protein, and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145466A1 (en) * 2006-06-14 2007-12-21 Lg Life Sciences Ltd. Gene family (lbfl313) associated with pancreatic cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145466A1 (en) * 2006-06-14 2007-12-21 Lg Life Sciences Ltd. Gene family (lbfl313) associated with pancreatic cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLARK, H. F. ET AL.: "The secreted protein discovery initiative(SPDI), a larg e-scale effort to identify novel human secreted and transmembrane proteins: a bioinformative assessment.", GENOME RESEARCH., vol. 13, no. 10, 15 September 2003 (2003-09-15), pages 2265 - 2270 *
DATABASE PROTEIN NCBI; 3 October 2003 (2003-10-03), Database accession no. AAQ89380 *
DATABASE UNIPROTKB NCBI; 10 June 2008 (2008-06-10), "Uncharacterized protein UNQ773/PR01567", Database accession no. Q96DA0 *
KIM, S. A. ET AL.: "Pancreatic adenocarcinoma up-regulated factor(PAUF), a no vel up-regulated secretory protein in pancreatic ductal adenocarcinoma.", CANCER SCIENCE., vol. 100, no. 5, 2 March 2009 (2009-03-02), pages 828 - 836 *

Also Published As

Publication number Publication date
WO2010036031A2 (en) 2010-04-01
KR20100034720A (en) 2010-04-01
KR101098186B1 (en) 2011-12-23
KR20110122807A (en) 2011-11-11

Similar Documents

Publication Publication Date Title
CY1115572T1 (en) CXCR4 ANTIBODIES AND USE OF THESE FOR CANCER TREATMENT
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
BR112014010161A2 (en) 43 kda dna tar protein binding monoclonal antibody (tdp-43) and its method of preparation and use in the treatment of tdp-43 proteinopathy, as well as compositions, polynucleotide, in vitro method and kit for diagnosing tdp-43 proteinopathy
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
UA90082C2 (en) Isolated monoclonal antibody which binds to and inhibits human cd25
WO2008070666A3 (en) Compositions and methods to treat cancer with cpg rich dna and cupredoxins
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
BRPI0412567A (en) isolated human antibody, method of treating a condition caused by increased ngf expression or increased ngf sensitivity in a patient, pharmaceutical composition, method for detecting ngf in a biological sample, nucleic acid molecule, host cell, isolated cell line, ngf-specific binding agent, isolated human antibody or immunologically functional immunoglobulin fragment or antigen binder thereof, polynucleotide, expression vector, medicament for treating a painful disorder or condition associated with increased ngf expression or increased sensitivity to ngf, and, use of a pharmaceutically effective amount of antibody
BR112012020373A8 (en) isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
MX2008009886A (en) Antibodies that bind par-2.
EA200870594A1 (en) BINDING HUMAN MOLECULES WITH KILLER ACTIVITY AGAINST ENTEROCCOKKKI AND THEIR APPLICATION
MX343748B (en) HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE INHIBITORS OF THE NGF TRAJECTORY.
UY31862A (en) IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
BRPI0822162A8 (en) method for treating nail or nail bed disease and pharmaceutical composition for topical treatment of nail or nail bed disease.
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
EA201070636A1 (en) INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT
JP2008530137A5 (en)
CY1115349T1 (en) CXCR4 CLEANED ANTIBODIES FOR CANCER TREATMENT
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
EA201591219A1 (en) ANTIBODIES AGAINST LAMP1 AND CONJUGATES ANTIBODIES AND MEDICINES AND THEIR APPLICATION
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
WO2010047938A3 (en) Mmp activation peptide detection in biological samples

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09816424

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09816424

Country of ref document: EP

Kind code of ref document: A2